Introduction
Vaccination against infectious diseases began ~ 200 years ago, and has proved to be a dramatically successful intervention. The formulations used have gone through many developments, and continue to do so, but vaccines are still unavailable for several pathogens. Design of vaccines against infectious organisms has considerable relevance for cancer, most obviously in those cancers which are known to be directly associated with viral infection (Table 1 ). The success of the vaccination program against hepatitis B in reducing the incidence of hepatoma in Taiwan illustrates the power of this approach [1] .
Recently, the strategy of using DNA vaccines, which contain genes encoding selected proteins of the target organism, has developed [2] . There is suddenly a chance to generate vaccines against difficult pathogens, and to take these stable vaccines into the field. Not only are DNA vaccines easy to construct and transport, but they also appear to enter the cell in a manner similar to that of an infectious virus [2] . This means that all pathways of the awaiting immune system are activated [2] . For prevention against infection, there are already trials of these novel vaccines taking place, using antigens from malaria [3] , hepatitis B [4] and HIV [5] , with promising results emerging [3] [4] [5] .
For cancer, preventative vaccines against cancer-associated viruses will be sought, but will only be applicable currently to 10%-20% of cancer ( Table 1 ). The challenge for most cancers is to activate immunity against tumor cells which are already present, even though they may be in low numbers in the setting of minimal residual disease. Interestingly, DNA vaccines may have the power to induce immunity in that situation, since, in a transgenic model with hepatitis B surface antigen as a secreted protein, a DNA vaccine against the antigen has been found to be capable of breaking tolerance [6] , In addition, a DNA vaccine against a heat shock protein has been reported to cure mice chronically infected with Mycobacterium tuberculosis [7] . Both these models demonstrate the important principle that a failing or tolerized immune system can be reactivated by an appropriate DNA vaccine. Even with this potential delivery system, several questions remain. The first relates to the nature and range of candidate tumor antigens, where again genetic technology is likely to add more to those already defined. Perhaps a more difficult problem is that of the immune status of patients, which is often damaged both by the disease process and by chemotherapy. Even here, there are new developments in treatment and transplantation which may help to reconstitute immune capacity. It appears that all the factors required for vaccination against cancer may be in place and that, at least for some tumors, we are in a position to test it in patients, with a hope of success.
DNA vaccines
The observation that naked plasmid DNA containing the gene encoding the enzyme P-galactosidase, when injected into mouse muscle, was able to generate functional enzyme, was a surprise [8] . Even more surprising was the subsequent finding that DNA encoding a nucleoprotein from influenza virus induced antibody, specific T-cell responses, and protective immunity against viral challenge [2] . These results have led to an explosion of interest in DNA vaccines against infectious organisms, and several are now in clinical trial [3] [4] [5] . It has also raised the possibility of applying a similar technology to cancer vaccines.
The mechanism of action of DNA vaccines is gradually being revealed. One unpredicted consequence of injecting the bacterial DNA backbone arises from the fact that bacterial DNA contains 'immunostimulatory sequences (ISSs)' not found in mammalian DNA. The sequences contain specific unmethylated CpG dinucleotide repeats with appropriate surrounding motifs, and the effect is to stimulate the innate immune response [9, 10] . The mediators released include IFNa, IFNp 1 , IL-12 and IL-18 from macrophages/monocytes, and IFNy from NK cells. IFNa, IFN|3, IL-12 and IL-18 are also inducers of IFNy, and the outcome of the rise in this cytokine is to promote the differentiation of naive T cells toT H l cells [9, 10] . DNA plasmids therefore have two components, first, the transcriptional unit driven by the powerful CMV promoter, and able to direct synthesis of tumor antigenic protein. Second, ISSs able to direct the immune response by release of IFNy (Figure 1) .
The favored injection sites for DNA vaccines have been muscle or skin, and the immunological outcome may differ between the sites. One difference arises from the use of the Gene Gun for intradermal injections, where it is clear that the dose of DNA required for induction of immunity is much lower than via an intramuscular injection [11] . This efficiency could be a consequence of direct transfection of Langerhans cells in the skin [12] . Injection into muscle generates a depot of antigen in the long-lived muscle cell [13] , but transfection of a small number of dendritic cells may also occur by this route [14] . Muscle cells are not able to prime the immune response directly, but can release soluble antigen into the surrounding fluid for uptake by antigen presenting cells (APCs) [13] . Induction of cytotoxic T cells (CTLs) appears to occur by 'cross-priming', a process by which antigen may be delivered to APCs either in membrane form [15] or via heat shock proteins [16] . Although the parallel release of IFNy drives the response down a T H 1 pathway (Figure 1 ), the pattern and longevity of immune outcome is influenced by the nature of the encoded antigen. For example, a strong CTL response will lead to destruction of muscle fibres and removal of the antigen depot [13] . It should be emphasized however, that there has been no evidence of significant muscle damage in mice, and muscle fibres can be replaced.
DNA vaccines against icliotypic determinants of B-eel I lymphoma
Idiotypic (Id) determinants of the clonal Ig of B-cell tumors provide clear tumor-specific antigens [17, 18] . The private Id determinants most useful for vaccination are derived from the complementarity-determining regions (CDRs) of the variable region of heavy and light chains, V H and V L . The CDR3 loop is unique for each B cell, largely due to the two sequential recombinatorial processes which occur first between a D-segment gene and J H , and then between V H and D. The imprecision in joining, with gain and loss of nucleotides at the junctions, is a device for generating diversity of sequence in this region. During maturation a normal B cell may accumulate further sequence diversity by somatic mutation. This adds to the variable amino acid sequences in CDRs which can compete to bind the limited antigen in the germinal centre, leading to selection for high affinity antibody. Neoplastic transformation preserves the unique V-region sequences in the proliferating clone, and they can then be considered as targets for immunotherapeutic strategies [18] . Idiotypic Ig is capable of inducing anti-idiotypic immunity in mice, which protects against challenge with lymphoma [18] [19] [20] . Id antigen performs best as a conjugate with KLH, and with adjuvant or cytokines as activators [20, 21] . However, although a small clinical trial is showing promising results [22] , the technical demands of preparing individual Id proteins drove us to explore a molecular biological route for vaccine preparation [23] . Obtaining the Id-encoding V H and V L genes from tumor biopsies or blood by PCR/cloning and sequencing proved to be relatively simple [23] . We chose to assemble the genes as single chain (sc) Fv with a 15 amino acid linker, and these were ligated into a plasmid with a promoter derived from CMV [23] . However, we were disappointed to find that this DNA vaccine failed to induce significant immune responses in mice, even if the scFv was derived from human Ig. The reason for this failure appears to be that scFv alone is not of sufficient interest to the patrolling cells of the immune system, even in the presence of the ISS sequences in the DNA backbone. Improved responses were being obtained in mice using mouse variable region sequences linked to human constant regions, indicating that xenogeneic constant regions were more immunogenic than xenogeneic scFv [24] . Clearly strategies to engage the attention of the immune system had to be explored.
DNA fusion gene vaccines
Since the major function of the immune system is to recognize and destroy pathogens, we decided to raise immunogenicity against scFv by fusing a gene encoding a pathogen-derived sequence to the 3' end of the scFv sequence. The sequence chosen encoded part of the Tetanus Toxin molecule, the C-terminal fragment, Fragment C (FrC) [25] . This sequence had already been shown to be capable of inducing protective immunity against challenge with Clostridium telani when delivered as a DNA vaccine [25] . The method of assembly, illustrated in Figure 2 , is designed to have the FrC sequence in the vaccine vector, so that each new assembled scFv sequence can be ligated in the upstream position, separated from FrC sequence by four amino acids [26] .
The results of adding in FrC sequence were striking, with the fusion gene inducing amplification of antibody responses in mice against 4/4 randomly selected human scFv sequences [26] . Importantly, the antibodies reacted with the patient's tumor IgM, and appeared to be largely Id-specific, consistent with proper folding of the scFv [26] . It was essential to fuse the scFv and FrC genes, since separate injection of the two plasmids raised only antibodies against FrC [27] . This indicates that CD4+ T cells specific for FrC are acting as helper cells for B-cells producing anti-Id, in a manner similar to a cognate hapten-carrier effect.
DNA fusion gene vaccines induce protective immunity against lymphoma and myeloma
The real test of a vaccine is to induce protective immunity against challenge with either a pathogen or with cancer cells. To assess performance of the DNA scFvFrC fusion vaccine, we used a mouse model of B-cell lymphoma, A31. We found that the fusion vaccine was able to induce anti-Id antibodies in syngeneic mice, and conferred protection against challenge with A31 cells [27] . Neither the DNA scFv alone or a control DNA scFv-FrC fusion gene from a different lymphoma, provided any protection, confirming that it was Id-specific. From previous studies using an Id protein vaccine, antibody is the likely mediator of protection [19] .
A similar DNA scFv-FrC design was tested in a myeloma model, 5T33, which resembles human myeloma in causing osteolytic lesions, and in secreting high levels of an IgG paraprotein [28] . In this case, the tumor cells are plasma cells and do not express Id at the cell surface, therefore anti-Id antibody is unlikely to be a mediator of protection. In fact, vaccination with Id protein in adjuvant completely failed to provide protection against challenge [27] . In contrast, vaccination with the DNA scFv-FrC, with the scFv sequence derived from 5T33 cells, induced protection against tumor challenge which appears to be mediated by T cells [27] . The vaccine also induced anti-Id antibodies which provide an indicator of the response, even though they are not protective [27] , Figure 3 shows the anti-Id response, and the increased One important question which concerns the use of FrC as a promoting sequence is whether pre-existing immunity against Tetanus Toxoid (TT) would affect the ability of patients to respond to the fusion gene product. Most patients will be immune to TT due to the widespread vaccination programme, and we have confirmed this by measuring levels of anti-TT antibodies. However, in the mouse models, we have found that pre-vaccination with TT affects the subsequent anti-Id response to DNA scFv-FrC only if the vaccine is given shortly before the DNA vaccine. It appears that after a few weeks, even though serum levels of anti-TT are still high, there is no interference with generation of anti-Id or of induction of protective immunity [27, and manuscript in preparation].
Although FrC sequence is proving to be a powerful activator of immunity against attached tumor antigens, it may not be the only sequence able to do this. It has been observed that attachment of a nonapeptide derived from IL-1|3 can also improve the immune response against scFv in the 38C13 mouse lymphoma model [29] . The mechanism of this interesting effect is not yet clear. A further report has described the use of sequences encoding chemokines to promote immunity against scFv [30] . Clearly there may be several options for activating immunity via attached proteins, and we need to understand more of their mode of action.
DNA fusion vaccines against alternative tumor antigens
There are many candidate tumor antigens which could be used in vaccines. Two of the most popular are carcinoembryonic antigen (CEA) and a mucin (MUC-1), both of which are expressed by certain epithelial malignancies [31, 32] . Although they are both expressed at the cell surface, and are heavily glycosylated, they have different molecular structures, with CEA being linked via a glycosyl phosphatidylinositol bond, and MUC-1 via a transmembrane sequence [31, 32] . For each antigen, various DNA vaccines have been designed and tested [33, 34] . To assess whether the DNA fusion design could have a role in promoting responses against these antigens, we collaborated with Dr K. Chester (Royal Free Hospital, London) (CEA) and Professor J. Taylor-Papadimitriou (Guy's Hospital, London) (MUC-1). In both cases, we found that fusion of FrC to the tumor antigen sequence strongly promoted the antibody response against the antigen. These findings open the possibility of using the fusion gene approach for alternative molecularly distinct tumor antigens.
Clinical trial of DNA vaccines against lymphoma
There are immense problems in modelling the disease setting which exists in patients with cancer. Many human tumors probably develop over a long period of time, possibly leading to tolerance against candidate antigens. Also, the effects of therapy on the tumor and on the immune system are difficult to assess. Treatment with autologous transplantation will clearly rescue a patient's bone marrow function, but whether it allows efficient reconstitution of immune capacity and escape from tolerance is unclear. Allogeneic transplantation may reconstitute a chimeric immune response, which could overcome tolerance. For these patients, infused donor lymphocytes appear to be able to attack tumor cells via rather poorly understood antigens. However, balancing the attack on tumor against an attack on host cells, which can lead to graft versus host disease, is presenting a challenge. If allogeneic transplantation can be managed, it creates an opportunity to increase the attack on tumor, and to add known immunological specificity, by vaccinating the donor with defined antigen prior to transplantation [35] .
For DNA scFv-FrC fusion vaccines, it is difficult to envisage toxic side effects. In fact, we have carried out a small trial of intramuscular injection of DNA scFv alone in seven patients with end-stage disease, in order to assess toxicity, with no deleterious consequences. There appears to be little danger from injecting DNA itself, and DNA vaccines against infectious diseases are undergoing trials in normal adults [3, 4] . The potential problems of integration into the genome or induction of pathological anti-DNA antibodies have not materialized [36] , perhaps reflecting the fact that bacterial DNA is often liberated during infections, and appears to present no hazard. The main danger might come from the gene chosen to put into the vaccine, and clearly the more tumor-specific the encoded protein is, the less the likelihood of inducing auotimmunity. In this respect, Id antigen is ideal, since the private Id determinants are unique, and there will be no immune response against the framework regions which are well represented in normal serum Ig.
The difficulty of modelling human cancer in mice, and the anticipated low or negligible toxicity of injection of DNA make pilot clinical trials the most sensible way of testing new vaccine designs. However, this requires new thinking by the regulatory authorities, since most clinical trials to date have been concerned to establish the level of toxicity as a first priority. The main concern for vaccines is whether they could induce autoimmunity and that potential danger should be evident from the nature of the antigen. In some cases, testing in transgenic mice will be appropriate for estimating this likelihood. The important question for vaccines is whether they will work in patients. It is quite ambitious to establish an ongoing immune response in cancer patients capable of selectively removing cancer cells. The pilot trials should be designed to demonstrate this effectiveness.
For our idiotypic DNA vaccines, the next stage of the clinical trial is now beginning, using DNA scFv-FrC fusion constructs in patients with low grade follicular centre lymphoma in first remission. The endpoint of this pilot study will be induction of antibodies against the two components of the vaccine, tumor-specific Id determinants and FrC of Tetanus Toxin. Responses against FrC will reveal whether patients are capable of raising an immune responses against the DNA-delivered protein, and should allow comparisons between different patient groups. Responses against scFv are the main goal, and, if successful, the trial will be expanded to a larger controlled trial to assess the effect on disease progression.
Concluding remarks
Knowledge of genetics, and availability of molecular biological technology, are opening possibilities for a rational approach to turning the immune system against cancer. Identification of tumor antigens is accelerating, and DNA vaccines could be a useful vehicle for delivering the encoded antigens to processing sites able to activate the full range of immune pathways. The ease of manipulation and relatively low cost of construction mean that assembly and testing of vaccines can be rapid. While testing in mice is a prerequisite, and should, where appropriate, include toxicity assessment in transgenic mice, it is not anticipated that these vaccines will have dangerous side-effects. Efficacy is the real goal, and pilot clinical trials should be facilitated so that designs can be modified and improved. More understanding of the tolerogenic effects of long term cancer, and the immune capacity of patients following disease or treatment, is required. Finally, knowledge of the interaction between pathogens and the immune response, and of operation of DNA vaccine against infectious organisms, is providing information which will underpin our efforts to use the weapons provided by genetics to subdue the cancer cell.
